Viking Therapeutics' stock rallies following early drug study data
Viking Therapeutics Inc. (VKTX) shares rose in the extended session Tuesday after the biotech drug developer said data from an early stage clinical study showed its drug candidate reduced liver fat levels. Viking shares rose as much as 7% after hours, following a 0.4% decline to close the regular session at $10.27. The company said a Phase 1 dosing study of its drug candidate VK2735 "showed reductions in subjects' liver fat content and plasma lipid levels" after 28 days of treatment, compared with a group given a placebo.
-Wallace Witkowski
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-17-23 1656ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States